Immune Thrombocytopenia
📧 Sign up to get email alerts when something new happens for Immune Thrombocytopenia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2017-10-04FDA Approved: PROMACTA — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for PROMACTA (eltrombopag olamine) submitted by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2017-08-23Clinical Trial Update: The Study of Different Dose Rituximab in the Treatment of ITP [Phase 4]
This clinical trial update reports a phase 4 study evaluating different doses of rituximab to treat immune thrombocytopenia.
-
CLINICAL_TRIALS research · 2017-08-09Clinical Trial Update: Lymphocyte Counts in Immune Thrombocytopenic Purpura
Clinical trial update on lymphocyte counts in patients with immune thrombocytopenia. Sponsored by Assiut University.
-
CLINICAL_TRIALS trial_result · 2017-07-26Clinical Trial Update: Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia [Phase 3]
Phase 3 trial evaluating the efficacy and safety of dapsone as a second-line option in adults with immune thrombocytopenia; current status i…
-
CLINICAL_TRIALS research · 2017-06-12Clinical Trial Update: Comparison Between Methyl Prednisolone and Intravenous Dexamethazone in Severe Immune Thrombocytopenic Purpra
This update reports a clinical trial comparing methylprednisolone to intravenous dexamethasone for severe immune thrombocytopenia, with the …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-06-09Clinical Trial Update: Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia [Phase 3]
Phase 3 trial comparing daily prednisone to pulsed dexamethasone in treatment-naïve adults with immune thrombocytopenia has completed. Resul…
-
CLINICAL_TRIALS trial_result · 2017-06-07Clinical Trial Update: Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia [Phase 3]
Phase 3 trial evaluating NewGam (intravenous immunoglobulin 10%) for primary immune thrombocytopenia; efficacy and safety results have been …
-
FDA approval · 2017-06-05FDA Approved: NPLATE — Supplemental Application (Amgen, Inc)
FDA approved Amgen's supplemental application for NPLATE (romiplostim), resulting in updated labeling for the product.
-
CLINICAL_TRIALS research · 2017-05-22Clinical Trial Update: The Effect and Frequency of Helicobacter Pylori Infection in Primary Immune Thrombocytopenic Patients
A clinical trial from Assiut University investigating the frequency and impact of Helicobacter pylori infection in patients with primary imm…
-
CLINICAL_TRIALS trial_result · 2017-05-05Clinical Trial Update: IGIV Study for Chronic ITP Patients Ages 3-70 [Phase 3]
A Phase 3 trial evaluating intravenous immunoglobulin for chronic immune thrombocytopenia in patients aged 3-70 has completed, with results …
-
CLINICAL_TRIALS research · 2017-04-26Clinical Trial Update: Genome-Wide Gene Expression Profiling of Patients With ITP Receiving Thrombopoietin Mimetics
A completed clinical trial report examining genome-wide gene expression profiling in patients with immune thrombocytopenia treated with thro…
-
CLINICAL_TRIALS research · 2017-03-23Clinical Trial Update: LENS - Long-term Eltrombopag Observational Study
The LENS long-term observational study evaluating eltrombopag in idiopathic thrombocytopenic purpura has completed.
-
FDA approval · 2017-03-09FDA Approved: PROMACTA — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for PROMACTA (eltrombopag olamine) by Novartis Pharmaceuticals Corporation. The action updates the p…
-
CLINICAL_TRIALS trial_result · 2017-02-20Clinical Trial Update: Prednisone or Dexamethasone in Newly Diagnosed, Previously Untreated Primary Immune Thrombocytopenic Purpura [Phase 3]
A Phase 3 trial comparing prednisone versus dexamethasone as initial therapy for newly diagnosed, untreated immune thrombocytopenia has comp…
-
CLINICAL_TRIALS trial_result · 2017-02-01Clinical Trial Update: A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013
A retrospective chart review of 33 pediatric patients with immune thrombocytopenia treated with romiplostim or eltrombopag between 2009 and …
-
CLINICAL_TRIALS research · 2017-01-26Clinical Trial Update: Clinical Trial of Gut Microbiota in the Management of Immune Thrombocytopenia [Phase 2]
This is a Phase 2 clinical trial investigating the role of gut microbiota in managing immune thrombocytopenia, sponsored by Shandong Univers…
-
CLINICAL_TRIALS trial_result · 2017-01-19Clinical Trial Update: Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients [Phase 3]
A Phase 3 pediatric trial evaluated romiplostim for safety and efficacy in immune thrombocytopenia, with results posted in January 2017.
-
CLINICAL_TRIALS other · 2017-01-06Clinical Trial Update: A Single-center Clinical Trial of Bortezomib in Management of Immune Thrombocytopenia (ITP) [Phase 2]
A Phase 2, single-center clinical trial investigating bortezomib for immune thrombocytopenia, sponsored by Shandong University; current stat…
-
CLINICAL_TRIALS research · 2016-11-18Clinical Trial Update: RP% Measurement by FCM as a Diagnostic Test for ITP
Describes a clinical trial evaluating RP% measurement by flow cytometry as a diagnostic test for immune thrombocytopenia. The current status…
-
FDA label_change · 2016-10-12FDA Approved: PROMACTA — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for PROMACTA (eltrombopag olamine) to update its labeling; this action may include changes to indica…
-
CLINICAL_TRIALS trial_result · 2016-09-07Clinical Trial Update: Regulatory B Cells and Chronic Immune Thrombocytopenia
Clinical trial update indicating the study on Regulatory B Cells in chronic immune thrombocytopenia has completed.
-
CLINICAL_TRIALS research · 2016-08-24Clinical Trial Update: Association of FcγRIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients [Phase 3]
A Phase 3 clinical trial investigates how FcγRIIIA polymorphism and THPO expression relate to response to eltrombopag in patients with refra…
-
CLINICAL_TRIALS trial_result · 2016-07-15Clinical Trial Update: Rituximab, Eltrombopag and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia [Phase 2]
Phase 2 clinical trial evaluating Rituximab, Eltrombopag, and Dexamethasone as frontline therapy for immune thrombocytopenia.
-
CLINICAL_TRIALS research · 2016-07-15Clinical Trial Update: DEX Combined With RTX, CSA and IVIG in the Management of Newly Diagnosed ITP Patients [Phase 3]
This document provides an update on a Phase 3 trial evaluating dexamethasone combined with rituximab, cyclosporine, and IVIG for newly diagn…
-
CLINICAL_TRIALS trial_result · 2016-05-25Clinical Trial Update: An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia [Phase 3]
An open-label Phase 3 study of IV-Globulin SN Inj.10% for immune thrombocytopenia has completed.